2Quinazolin4(3H)one derivatives as dual EGFR and VEGFR2 inhibitors: Design, synthesis, molecular docking and anticancer activity

Pharmacology, Toxicology and Pharmaceutical Science

1. Epidermal Growth Factor Receptor 100%
2. Malignant Neoplasm 50%
3. Anticarcinogen 16%
4. Tumor Growth 13%
5. Adverse Event 13%
6. Vasculotropin 10%
7. Therapeutic Effect 6%
8. Neovascularization (Pathology) 6%
9. Protein Tyrosine Kinase 6%
10. Mortality Rate 6%
11. Gamma Urogastrone 6%
12. Phosphotransferase Inhibitor 6%
13. Drug Resistance 6%
14. Cancer Incidence 6%
15. Antiangiogenic Therapy 6%